Bladder Cancer
EU BLADDER CANCER PARTNER
World Partner
An Introduction to Bladder Cancer
Bladder cancer is the most common malignancy involving the urinary system. While cisplatin-based chemotherapy and Bacillus Calmette-Guérin (BCG) remains the standard of care for muscle-invasive and non-muscle-invasive disease, respectively, the development of immune checkpoint inhibitors has transformed the management of advanced urothelial cancer, with atezolizumab, durvalumab and avelumab being approved for use following platinum-based chemotherapy or in as first-line treatment in platinum-ineligible patients. However, many patients fail to respond to these agents, and predictive biomarkers remain an unmet need. Emerging treatment options include combined immunotherapy approaches, targeted therapies and antibody-drug conjugates.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.
At #ASCO25, Professor Dickon Hayne presented results from the ANZUP 1301 trial showing that adding mitomycin C to BCG may offer a well-tolerated, effective option for high-risk NMIBC. The combination reduced BCG use by 40% – a significant finding amid global shortages – with encouraging efficacy and safety signals.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
This May, the World Bladder Cancer Patient Coalition (WBCPC) is launching Bladder Cancer Awareness Month 2025 under the theme “Feeling Unsure? Get Checked”. The campaign highlights the importance of recognising blood in urine as a symptom of bladder cancer and acting quickly to seek medical advice.
Bladder cancer is one of the most common malignancies in the USA, with an estimated 81,180 new cases and 17,100 deaths in 2022.1 Advanced urothelial carcinoma (aUC) includes both locally advanced, unresectable and metastatic urothelial cancer. About 5% of all bladder cancer cases present ...
Bladder cancer (BC) is the sixth most common cancer in the world, accounting for 81,180 estimated new cases and 17,100 deaths in 2022.1 BC is most frequently diagnosed among people aged 65–74 years.1 For patients with disease limited to the bladder, the depth of ...
Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress. Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
